Vimarsana
Biggest News Aggregation in the World

Page 4 - Nasdaq Cccc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq Cccc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq Cccc Today - Breaking & Trending Today

C4 Therapeutics, Inc. (NASDAQ:CCCC) Receives $9.86 Average PT from Brokerages - Vimarsana News

C4 Therapeutics, Inc. (NASDAQ:CCCC) Receives $9.86 Average PT from Brokerages

Shares of C4 Therapeutics, Inc. (NASDAQ:CCCC – Get Rating) have received an average recommendation of “Hold” from the seven research firms that are presently covering the company, Marketbeat reports. Two analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and two have assigned a buy recommendation to the company. […]

C4 Therapeutics (NASDAQ:CCCC) PT Lowered to $10.00 - Vimarsana News

C4 Therapeutics (NASDAQ:CCCC) PT Lowered to $10.00

C4 Therapeutics (NASDAQ:CCCC – Get Rating) had its price target lowered by Evercore ISI to $10.00 in a report released on Tuesday morning, The Fly reports. Several other research firms also recently weighed in on CCCC. Credit Suisse Group raised shares of C4 Therapeutics from an underperform rating to a neutral rating and decreased their […]

Source: wkrb13.com
Brokerages Set C4 Therapeutics, Inc. (NASDAQ:CCCC) PT at $9.83 - Vimarsana News

Brokerages Set C4 Therapeutics, Inc. (NASDAQ:CCCC) PT at $9.83

C4 Therapeutics, Inc. (NASDAQ:CCCC – Get Rating) has been assigned an average rating of “Hold” from the eight analysts that are currently covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, three have given a hold recommendation and one has given a buy recommendation to the company. The […]

C4 Therapeutics, Inc. (NASDAQ:CCCC) Given Average Rating of "Hold" by Brokerages - Vimarsana News

C4 Therapeutics, Inc. (NASDAQ:CCCC) Given Average Rating of "Hold" by Brokerages

C4 Therapeutics, Inc. (NASDAQ:CCCC – Get Rating) has earned a consensus recommendation of “Hold” from the seven research firms that are presently covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and one has issued a buy recommendation on the company. The average […]

Source: wkrb13.com
HC Wainwright Cuts C4 Therapeutics (NASDAQ:CCCC) Price Target to $25.00 - Vimarsana News

HC Wainwright Cuts C4 Therapeutics (NASDAQ:CCCC) Price Target to $25.00

C4 Therapeutics (NASDAQ:CCCC – Get Rating) had its price target cut by HC Wainwright from $35.00 to $25.00 in a research report report published on Monday, The Fly reports. HC Wainwright also issued estimates for C4 Therapeutics’ FY2023 earnings at ($2.84) EPS, FY2024 earnings at ($3.06) EPS, FY2025 earnings at ($3.42) EPS, FY2026 earnings at […]